Multi-centers, Open-Label, Phase 2 Study to Evaluate the Efficacy and Safety of Donor-Derived CD7 CAR T Cells in Subjects With Relapsed or Refractory T-cell Leukemia/Lymphoma
Beijing Boren Hospital
Beijing Boren Hospital
M.D. Anderson Cancer Center
Beijing Boren Hospital
Hebei Senlang Biotechnology Inc., Ltd.
Angimmune LLC
BioCryst Pharmaceuticals
National Institutes of Health Clinical Center (CC)
National Institutes of Health Clinical Center (CC)